Home Blog

0 8

Patent Number: 9,121,037

Grant date: December 31, 1969
Priority date: January 23, 2009
Estimated expiration date: January 23, 2029
Inventor(s): Kusk; Philip (Lynge, DK), Wahlberg; Lars Ulrik (Tiverton, RI)
Assignee(s): NsGene A/S (Ballerup, DK)
External link: USPTO website

Abstract:

The present invention relates to generation of cell lines expressing recombinant proteins for use in naked and encapsulated cell biodelivery of secreted therapeutic molecules. In one embodiment the cell line is human. In another aspect of the invention the transposon system is used for generating a cell line for secretion of a biologically active polypeptide.

0 7

Patent Number: 9,121,011

Grant date: December 31, 1969
Priority date: January 26, 2010
Estimated expiration date: January 26, 2030
Inventor(s): Osafune; Kenji (Kyoto, JP), Mae; Shin-ichi (Kyoto, JP), Kajiwara; Masatoshi (Kyoto, JP)
Assignee(s): KYOTO UNIVERSITY (Kyoto-shi, JP)
External link: USPTO website

Abstract:

The present invention relates to: a method for producing an intermediate mesoderm cell from a human pluripotent stem cell, comprising a step of culturing the human pluripotent stem cell in a medium containing Activin A and Wnt or a functional equivalent of Wnt and a step of culturing cells in a medium containing BMP and Wnt or a functional equivalent of Wnt; to a method for producing a metanephric cell from the intermediate mesoderm cell produced by the first method; to a human pluripotent stem cell having a foreign reporter gene in the chromosome wherein the gene is expressed interlocked with the expression of endogenous OSR1; to a method for screening for an inducer for differentiation into intermediate mesoderm using the human pluripotent stem cell; and to a kit for inducing the differentiation into an intermediate mesoderm cell.

0 7

Patent Number: 9,121,008

Grant date: December 31, 1969
Priority date: January 26, 2010
Estimated expiration date: August 31, 2025
Inventor(s): Tsai; Schickwann (Salt Lake City, UT)
Assignee(s): University of Utah Research Foundation (Salt Lake City, UT)
External link: USPTO website

Abstract:

The invention relates to natural killer cells and methods for the development of immortalized natural killer cells and use of the natural killer cells. A growth and culture system is described that supports increased natural killer cell development, and provides for the establishment of continuous natural killer cell lines. Additionally, the disclosed method for generating natural killer cells may be used to produce large numbers of natural killer cells for therapeutic applications and for natural killer cell research.

0 8

Patent Number: 9,121,007

Grant date: December 31, 1969
Priority date: January 26, 2010
Estimated expiration date: January 26, 2030
Inventor(s): Zhang; Xiaokui (Livingston, NJ), Yaccoby; Shmuel (Little Rock, AR), Abramson; Sascha (Hillsborough, NJ), Hariri; Robert J. (Bernardsville, NJ)
Assignee(s): ANTHROGENESIS CORPORATIN (Warren, NJ)
External link: USPTO website

Abstract:

Provided herein are methods of suppression of proliferation and growth of cells of bone-related cancers, e.g., multiple myeloma or chondrosarcoma cells, using placental cells, e.g., the placental stem cells described herein, and populations of such placental cells. Also provided herein are methods of treating individuals having cells of a bone-related cancer.

0 8

Patent Number: 9,119,884

Grant date: December 31, 1969
Priority date: September 02, 2010
Estimated expiration date: September 02, 2030
Inventor(s): Lam; Kit S. (Oakland, CA), Liu; Ruiwu (Oakland, CA), Yao; Wei (Oakland, CA), Lane; Nancy (Oakland, CA)
Assignee(s): The Regents of the University of California (Oakland, CA)
External link: USPTO website

Abstract:

The present invention provides compounds and pharmaceutical compositions of a peptidomimetic ligand, e.g. LLP2A, conjugated with a bisphosphonate drug, e.g. Alendronate. The compounds and pharmaceutical compositions of the present invention are useful in the treatment of osteoporosis and for the promotion of bone growth due to their specificity for the .alpha..sub.4.beta..sub.1 integrin on mesenchymal stem cells and for the surface of bone.

0 8

Patent Number: 9,119,862

Grant date: December 31, 1969
Priority date: June 23, 2011
Estimated expiration date: June 23, 2031
Inventor(s): Prabhu; Kumble Sandeep (State College, PA), Paulson; Robert Frank (State College, PA), Hegde; Shailaja (Union, KY), Kaushal; Naveen (Chandigarh, IN), Gandhi; Ujjawal Hitendra (New York, NY)
Assignee(s): The Penn State Research Foundation (University Park, PA)
External link: USPTO website

Abstract:

Compositions, kits and methods for treating leukemia in a subject (e.g., human) include a first anti-cancer drug consisting of: .DELTA..sup.12-prostaglandin J.sub.3 or a derivative thereof, or a prostaglandin D receptor (DP) agonist. The compositions may further include a second anti-cancer drug. .DELTA..sup.12-prostaglandin J.sub.3 is a stable metabolite of omega-3 fatty acid, eicosapentaenoic acid (EPA), and was discovered to have anti-leukemic properties. .DELTA..sup.12-prostaglandin J.sub.3 was shown to be highly effective in eradicating the leukemia stem cells (LSC) in two murine models of leukemia, thus increasing the survival of the mice. DP agonists were shown to induce apoptosis of human primary Acute Myelogenous Leukemia cells and may be used in compositions, kits and methods for treating leukemia in a subject. The compositions, kits and methods may be particularly useful for treating human subjects who are resistant to one or more anti-cancer drugs.

0 8

Patent Number: 9,119,370

Grant date: December 31, 1969
Priority date: June 23, 2011
Estimated expiration date: June 23, 2031
Inventor(s): Smits; Egbert Carolus Johannes (Zevenbergen, NL), Morice; Clement Michel Bernard (Vlaardingen, NL), Moor; Cornelis Marinus (Monster, NL)
Assignee(s): RIJK ZWAAN ZAADTEELT EN ZAADHANDEL B.V. (De Lier, NL)
External link: USPTO website

Abstract:

The present invention relates to Lactuca sativa seed designated 79-99 RZ, which exhibits resistance to downy mildew (Bremia lactucae Regel.) races Bl:1 to Bl:28, lettuce mosaic virus (LMV) and currant-lettuce aphid (Nasonovia ribisnigri) and which has deeply red, deeply-incised, nicely-filled leaves. The present invention also relates to a Lactuca sativa plant produced by growing the 79-99 RZ seed. The invention further relates to methods for producing the lettuce cultivar, represented by lettuce variety 79-99 RZ.

0 8

Patent Number: 9,119,369

Grant date: December 31, 1969
Priority date: June 23, 2011
Estimated expiration date: June 23, 2031
Inventor(s): Moor; Cornelis Marinus (Monster, NL), Smits; Egbert Carolus Johannes (Zevenbergen, NL)
Assignee(s): RIJK ZWAAN ZAADTEELT EN ZAADHANDEL B.V. (De Lier, NL)
External link: USPTO website

Abstract:

The present invention relates to a Lactuca sativa seed designated 79-163 RZ, which exhibits resistance to downy mildew (Bremia lactucae Regel.) races B1:1 to B1:28, and which has an extraordinary high number of red-colored, oakleaf-shaped leaves of substantially equal size. The present invention also relates to a Lactuca sativa plant produced by growing the 79-163 RZ seed. The invention further relates to methods for producing the lettuce cultivar, represented by lettuce variety 79-163 RZ.

0 8

Patent Number: 9,119,367

Grant date: December 31, 1969
Estimated expiration date: September 02, 2035
Inventor(s): Moor; Cornelis Marinus (Monster, NL), Smits; Egbert Carolus Johannes (Zevenbergen, NL)
Assignee(s): RIJK ZWAAN ZAADTEELT ENZAADHANDEL B.V. (De Lier, NL)
External link: USPTO website

Abstract:

The present invention relates to a Lactuca sativa seed designated 79-41 RZ, which may exhibit resistance to downy mildew (Bremia lactucae Regel.), currant-lettuce aphid (Nasonovia ribis-nigri) and Lettuce Mosaic Virus (LMV), and which may have light green, moderately glossy, deeply-incised, strongly undulated leaves. The present invention also relates to a Lactuca sativa plant produced by growing the 79-41 seed. The invention further relates to methods for producing the lettuce cultivar, represented by lettuce variety 79-41 RZ.

0 14

Patent Number: 9,115,345

Grant date: December 31, 1969
Priority date: March 20, 2001
Estimated expiration date: March 20, 2021
Inventor(s): Morrisey; Edward E. (Newtown Square, PA)
Assignee(s): The Trustees Of The University Of Pennsylvania (Philadelphia, PA)
External link: USPTO website

Abstract:

Compositions and methods for inducing the formation of an induced pluripotential stem (iPS) cell from a somatic cell are disclosed. The compositions comprise miR 302-367 cluster and valproic acid. Further disclosed are methods for treatment of a disease or condition in a subject through the use of the compositions.